Sanofi Achieves 7% Q3 Sales Growth Amid Product Launch Success
Paris, Friday, 24 October 2025.
Sanofi’s Q3 sales grew by 7%, driven by a 57.1% increase from new product launches, with Dupixent sales surpassing €4 billion for the first time, highlighting strong market performance.
Strong Q3 Results Amid Market Challenges
Sanofi, listed under the ticker symbol SNY, has reported robust third-quarter financial results for 2025, achieving a 7.0% increase in sales at constant exchange rates. The pharmaceutical giant’s performance was bolstered by the successful launch of new products, which drove a 57.1% increase in sales, amounting to €1.0 billion. Notably, the sales of Dupixent, a key product in Sanofi’s portfolio, surged by 26.2%, surpassing €4 billion for the first time in a single quarter [1][2].
Product Launches and Market Expansion
Sanofi’s strategic focus on expanding its product portfolio has played a pivotal role in its recent success. The company launched several new pharmaceutical products, including ALTUVIIIO and Ayvakit, which significantly contributed to the revenue growth. This strategic expansion underscores the company’s commitment to addressing diverse healthcare needs through innovative solutions [1][3]. Furthermore, Sanofi’s business earnings per share (EPS) increased by 13.2% to €2.91, reflecting the company’s operational efficiency and strategic investments in research and development [2][4].
Challenges in Vaccine Sales
Despite the overall positive financial performance, Sanofi faced challenges in its vaccine division, where sales declined by 7.8% to €3.4 billion. This decrease was primarily attributed to lower sales of influenza vaccines, a sector that has been affected by fluctuating market demands and competitive pressures [3][4]. However, the company’s diverse product range and strategic investments in other areas have helped mitigate the impact of these challenges [1][2].
Future Outlook and Strategic Plans
Looking ahead, Sanofi continues to demonstrate resilience and strategic foresight. The company has secured two regulatory approvals for Wayrilz in the U.S. for immune thrombocytopenia and Tzield in China for delaying the onset of stage 3 type 1 diabetes, further expanding its therapeutic offerings [2][3]. Additionally, Sanofi is actively pursuing new regulatory submissions and phase 3 study initiations, reinforcing its commitment to innovation and market leadership. The company remains optimistic about sustaining its growth trajectory into 2026, with plans to further enhance its financial performance through strategic investments and operational efficiencies [1][4].